Corvus Pharmaceuticals (#CRVS) announced the publication in Blood of final Phase 1 data from its Soquelitinib Phase 1/1b trial in T-cell lymphoma. 🔹 Key Highlights 🧬 Final Phase 1/1b data published in Blood. 💊 The study evaluates soquelitinib. 🧪 Trial focused on T-cell lymphoma. 📊 Publication provides additional clinical data supporting development of the program. 🔬 The data add to Corvus Pharmaceuticals' clinical development portfolio. 💡 Why It Matters The publication provides additional visibility into soquelitinib's clinical development in T-cell lymphoma and represents another milestone as Corvus advances its oncology pipeline. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified